Risk, Prevention, and Screening (MC Liu, Section Editor)

Current Breast Cancer Reports

, Volume 4, Issue 3, pp 207-215

First online:

Tamoxifen versus Raloxifene versus Exemestane for Chemoprevention

  • Laura ReimersAffiliated withDepartment of Epidemiology, Mailman School of Public Health, Columbia University
  • , Katherine D. CrewAffiliated withDepartment of Epidemiology, Mailman School of Public Health, Columbia UniversityDepartment of Medicine, College of Physicians and Surgeons, Columbia UniversityHerbert Irving Comprehensive Cancer Center, Columbia University Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Clinical trial data on selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) have demonstrated reduced breast cancer incidence in the prevention setting among high-risk women. We conducted an extensive review of clinical trials and recent published reports of barriers to uptake of breast cancer chemoprevention, to provide health care professionals with information to improve decision making regarding chemoprevention. Despite the positive results of these trials, uptake of chemoprevention has been low due to barriers in identifying high-risk women, lack of understanding of risks and benefits, as well as concerns about side effects. Interventions designed to increase uptake have met with limited success. Clinicians can support women in informed decision making about SERMs and AIs by effectively communicating breast cancer risk and enhancing knowledge about the risks and benefits of chemoprevention. Promoting uptake and adherence to chemoprevention holds promise for reducing the public health burden of this disease.


Breast cancer Chemoprevention Selective estrogen receptor modulator SERM Aromatase inhibitor AI Prevention Risk